Form 4: Solid Biosciences CFO Sells Shares for Tax Obligations

Solid Biosciences CFO Kevin Tan sold 5,404 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Kevin Tan, CFO & Treasurer of Solid Biosciences Inc. (SLDB), reported transactions involving the company's common stock.
• On February 13, 2026, 10,625 restricted stock units (RSUs) vested and were converted into common stock.
• These RSUs were part of a grant made on February 13, 2025, which vests over four years, with 25% vesting annually.
• Following the vesting, on February 18, 2026, Mr. Tan sold 5,404 shares of common stock at a weighted average price of $5.8233 per share.
• The sale was executed to cover withholding taxes associated with the RSU vesting, as per a pre-arranged automatic sales instruction letter adopted on August 15, 2024.
• This transaction was not a discretionary trade by Mr. Tan.
• After these transactions, Mr. Tan beneficially owns 99,422 shares of common stock directly and 21,250 derivative securities (RSUs) directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction related to executive compensation and tax obligations, thus having a neutral impact on sentiment.

Positives

• The vesting of 10,625 restricted stock units represents a component of executive compensation for the CFO, indicating continued alignment with company performance.

Negatives

• No inherent negatives are identified, as the sale of 5,404 shares was a non-discretionary transaction solely to cover tax withholding obligations related to RSU vesting.

Future Outlook

The remaining 21,250 Restricted Stock Units held by Mr. Tan are expected to vest over the next three years, with 25% of the original grant vesting on each anniversary of the February 13, 2025, grant date.

Management Comments

• The sale of 5,404 shares was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Tan on August 15, 2024, effecting the sell-to-cover election.
• The sale does not represent a discretionary trade by Mr. Tan.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a common and routine practice for executives receiving equity compensation, such as Restricted Stock Units, to satisfy tax obligations upon vesting. This type of transaction is generally not indicative of an executive's sentiment regarding the company's future prospects, unlike discretionary open-market sales.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence.
• Employees: No direct impact.

Next Steps

• Future vesting of the remaining 21,250 Restricted Stock Units on subsequent anniversaries of the February 13, 2025, grant date.

Key Dates

Keywords

Solid Biosciences, SLDB, Kevin Tan, CFO, Insider Trading, Form 4, Restricted Stock Units, Equity Compensation, Sell-to-Cover, Tax Withholding